Imunon, Inc. Common Stock (IMNN)
ImmunoGen, Inc. (IMNN) is a biotechnology company focused on the development of targeted antibody-drug conjugates (ADCs) for the treatment of cancer. The company leverages its proprietary ADC technology to create therapies designed to deliver potent cancer-killing agents directly to tumor cells, aiming to improve efficacy and reduce side effects associated with traditional chemotherapy.
Company News
IMUNON announced progress in its Phase 3 OVATION 3 clinical trial for IMNN-001, a DNA-mediated immunotherapy targeting advanced ovarian cancer. The company has enrolled its first patient, implemented cost conservation measures, and introduced a 15% stock dividend to shareholders.
Shares of Bumble Inc. (NASDAQ: BMBL) fell sharply during Wednesday’s session following weak quarterly results. Bumble reported quarterly losses of 19 cents per share which missed the analyst consensus estimate of 12 cents per share. The company reported quarterly sales of $273.64 million which missed the analyst consensus estimate of $275.29 m...